# Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

> **NCT00553410** · PHASE3 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 4884 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00553410
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2018-04
- **Final completion:** 2019-05-15
- **Target enrollment:** 4884 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553410, "Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00553410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*